Zacks Research Daily has highlighted 16 major stocks in its latest research output, with JPMorgan Chase & Co. (NYSE: JPM), Novartis AG (NYSE: NVS), and Qualcomm Inc. (NASDAQ: QCOM) among the featured names.
JPMorgan shares have gained 2.7% over the past six months, trailing the Zacks Financial – Investment Bank industry’s gain of 5.8% over the same period.
The bank’s consumer franchise continues to expand, with U.S. branch builds and plans for Chase digital expansion in Europe following successful launches in the U.K. and Germany.
Market revenues and investment banking fees are expected to remain strong, while healthy asset management activity will continue to support fee income growth.
Despite these positives, mortgage dynamics remain mixed, expenses are rising due to compensation and technology spend, and a tough macro backdrop raises asset quality concerns.
Novartis shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past six months, gaining 12.2% compared to the industry’s 6.1% rise.
The company faces headwinds from generic competition for its blockbuster drug Entresto in the United States, with 2026 marking the largest patent cliff in Novartis history.
Analysts estimate Pluvicto and Kisqali will deliver compound annual growth rates of 26.1% and 24.1%, respectively, over the next three years, supporting the mid-term outlook.
Key upcoming catalysts across cardiovascular, immunology and rare disease programs, alongside recent acquisitions, are expected to bolster Novartis’s pipeline and growth trajectory.
Qualcomm shares have gained 14.1% over the past six months, though that trails the Zacks Electronics – Semiconductors industry’s gain of 48.9% during the same stretch.
The company is pivoting away from a handset-centric model, with more than 1 million cars now operating advanced driver assistance systems and autonomy features on Snapdragon Ride processors.
The Alphawave buyout adds high-speed wired connectivity IP and custom silicon capabilities, positioning Qualcomm to accelerate its expansion into data centers.
However, uncertain memory supply and pricing are keeping chipset shipments below end demand, and growing in-house chip development by major OEMs poses a longer-term market share risk.
Micro-cap stocks Genie Energy Ltd. (NYSE: GNE), with a market capitalization of $386.24 million, and ImmuCell Corp. (NASDAQ: ICCC), with a market capitalization of $88.57 million, were also featured in today’s research roundup.
Genie Energy shares have gained 6.6% over the past six months, while ImmuCell shares have surged 60% over the same period, dramatically outpacing the Zacks Medical – Products industry’s decline of 27.3%.
Other noteworthy reports featured today include Genuine Parts Co. (NYSE: GPC), Jones Lang LaSalle Inc. (NYSE: JLL), and Oklo Inc. (NYSE: OKLO).
